Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 October 2022 | Story Nonsindiso Qwabe
Qwaqwa research conference
Unpacking the role of research in society. From left: Lukhona Mnguni, Prof Pearl Sithole, Prof Dipane Hlalele, and Prof Percy Hlangothi

From socio-political dynamics and creativity in the Basotho language, to the improvement of water conditions in the upper Tugela River and antifungal studies of Cydonia oblonga extracts (known as kwepere in Sesotho) – these are just some of the highlights of the research presented at the UFS Qwaqwa Campus research conference.

With a theme focused on research as a tool for the betterment of humanity, the two-day research conference provided a space for the campus to showcase its research for sustainable development in the Afromontane region and beyond, conducted by academics and postgraduate students alike. The two-day event comprised oral student and staff presentations and sessions, with shorter presentations on the second day.

As global trends continue to challenge society to solve big and immediate problems, there has been a natural turn towards research that can make a lasting impact on local and global platforms. Through student and academic presentations, the conference provided insights into how the UFS is playing an active role in responding to some of these challenges by being outwardly focused in their approaches to problem-solving.

Balancing the sciences, industry, and society

With an intentional focus on interdisciplinarity, the guest speakers – all in different science fields – offered solutions to conducting impactful research through the lens of their own work. Prof Percy Hlangothi is currently an Associate Professor of Physical and Polymer Chemistry at Nelson Mandela University (NMU) and inaugural Director of the Centre for Rubber Science and Technology, a research entity in the Faculty of Science at the same institution. By describing his work, particularly on the production of tyres, he focused on the importance of achieving rapport between the sciences, industry, and society.

The second keynote speaker was Lukhona Mnguni, a governance, politics and development specialist and PhD candidate in Political Science at the University of KwaZulu-Natal. He currently serves as the Head of Policy and Research at the Rivonia Circle. Mnguni focused his talk on the breakthroughs of research as stemming from people, and not academic disciplines themselves. Mnguni issued a hard call towards a reflection of what the intellectual and scholarly quest for knowledge is doing to society, emphasising the need for societal involvement in issues pertaining to crises in society.

Prof Dipane Hlalele, Professor of Education at UKZN and a C2 NRF-rated researcher (2022-2027), was the final speaker for the conference. He anchored his talk on the importance of having philosophical frames behind scholarship, and spoke against approaching rural areas as lacking knowledge, to a stance of mutual understanding of knowledge schemes and models of intervention.

Campus focused on making an impact outwardly

Marking the opening of the conference, Dr Martin Mandew, Qwaqwa Campus Principal, said the campus was trying to punch above its weight and evolve its research and knowledge outputs. “We cannot just be consumers of knowledge and finished products that come from abroad. We have to produce our own knowledge that speaks to our own unique circumstances and makes complete sense of our capacities,” he said.

The conference also served as the launch platform for the campus research strategy. During the launch, Prof Pearl Sithole, Campus Vice-Principal: Academic and Research, said the strategy was centred on five frontiers. “We are trying to align what we do outwardly in terms of impact and are working on ourselves as per the commitments of the strategy. We do this excellently, because we want to advance knowledge – there is no question about that – and we put pressure on each other to do that. It does not mean that it will be easy, but we are going to engineer it such that originality and the advancement of knowledge is happening.”

The conference concluded with a prize-giving session for the best oral student presentations.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept